Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures
Developing novel drugs for systemic targeted radiation therapy (STRT)
Proceeds will be used to advance lead radiopharmaceutical product, s... Biopharmaceuticals, Oncology, Venture Capital Ariceum Therapeutics, satoreotide, radiopharmaceutical
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Neurology | Pharmaceuticals | Radiation Therapy | Venture Capital